Bringing breakthrough therapeutics to patients with serious illnesses
Eikon Therapeutics is a clinical-stage biopharmaceutical company that has built the world's first high-throughput single-molecule tracking (htSMT) platform, enabling visualization of hundreds of thousands of protein motion events in living cells in under a second. Founded on Nobel Prize-winning super-resolution microscopy by Eric Betzig, Eikon uses this platform to discover and develop breakthrough oncology and neurological therapeutics. The company completed an IPO in early 2026, raising $381 million.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2026
Feb 2026
Feb 2025
Jun 2023
Jan 2022
Jan 2021
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
